-
公开(公告)号：US11712469B2
公开(公告)日：2023-08-01
申请号：US16847059
申请日：2020-04-13
IPC分类号： A61K39/395 , C12N5/0783 , C07K14/705 , A61K39/00 , A61K35/17 , C07K14/725 , C07K16/28 , C07K16/30 , A61K39/44 , A61K35/15 , C12N9/24
CPC分类号： A61K39/39558 , A61K35/15 , A61K35/17 , A61K39/0011 , A61K39/00117 , A61K39/00118 , A61K39/001102 , A61K39/001106 , A61K39/001109 , A61K39/001113 , A61K39/001114 , A61K39/001117 , A61K39/001119 , A61K39/001124 , A61K39/001128 , A61K39/001129 , A61K39/001153 , A61K39/001157 , A61K39/001166 , A61K39/001168 , A61K39/001171 , A61K39/001182 , A61K39/001186 , A61K39/001188 , A61K39/001193 , A61K39/001195 , A61K39/44 , C07K14/705 , C07K14/7051 , C07K14/70503 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/2809 , C07K16/30 , C07K16/3069 , C12N5/0638 , C12N9/2402 , A61K2039/5156 , C07K2317/31 , C07K2317/622 , C07K2317/74 , C07K2317/92 , C07K2319/33 , C07K2319/74 , C12N2510/00 , C12N2999/002
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
-
公开(公告)号：US20220275363A1
公开(公告)日：2022-09-01
申请号：US17697028
申请日：2022-03-17
发明人： Michel Sadelain , Ashlesha Odak
IPC分类号： C12N15/10 , C07K14/725 , C12N15/90 , C12N9/22
摘要： The present disclosure provides methods for identifying genomic safe harbors in a genome (e.g., a human genome).
-
公开(公告)号：US20220211761A1
公开(公告)日：2022-07-07
申请号：US17697044
申请日：2022-03-17
发明人： Michel Sadelain , Ashlesha Odak
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , A61P35/00 , C12N15/62 , C07K16/28
摘要： The present disclosure provides genomic safe harbors (GSHs) at which transgenes can be integrated for stable and reliable expression, without disrupting the expression or regulation of the endogenous genes. The present disclosure further provides genetically modified cells comprising a transgene that is integrated within the GSHs disclosed herein. The present disclosure further provides compositions, kits, and formulations comprising genetically modified cells disclosed herein.
-
公开(公告)号：US20220031754A1
公开(公告)日：2022-02-03
申请号：US17505515
申请日：2021-10-19
IPC分类号： A61K35/17 , C07K14/725 , C07K16/28
摘要： The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
-
公开(公告)号：US20210246221A1
公开(公告)日：2021-08-12
申请号：US17233994
申请日：2021-04-19
发明人： Michel Sadelain , David J. Hansen
IPC分类号： C07K16/30 , C07K14/725 , C07K14/705 , A61K35/17 , A61P35/00
摘要： The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., pancreatic cancer). It relates to antigen recognizing receptor (e.g., chimeric antigen receptors (CARs)) that specifically target Sialyl Lewis A (e.g., human Sialyl Lewis A), and immunoresponsive cells comprising such CARs. The presently disclosed Sialyl Lewis A-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
-
公开(公告)号：US20210030804A1
公开(公告)日：2021-02-04
申请号：US17075142
申请日：2020-10-20
IPC分类号： A61K35/17 , C07K16/28 , C07K14/725
摘要： The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
-
公开(公告)号：US20200325223A1
公开(公告)日：2020-10-15
申请号：US16912291
申请日：2020-06-25
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
IPC分类号： C07K16/28 , C07K14/725 , C07K16/30 , A61P35/00 , A61K35/17 , C07K14/705
摘要： The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
-
公开(公告)号：US20200268793A1
公开(公告)日：2020-08-27
申请号：US15931027
申请日：2020-05-13
IPC分类号： A61K35/17 , C07K14/715 , C07K14/725 , C07K14/705 , A01K67/027
摘要： The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable IL-1Ra polypeptide.
-
公开(公告)号：US20190307800A1
公开(公告)日：2019-10-10
申请号：US16419865
申请日：2019-05-22
IPC分类号： A61K35/17 , C07K14/705
摘要： The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
-
公开(公告)号：US20170081405A1
公开(公告)日：2017-03-23
申请号：US15368278
申请日：2016-12-02
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , The U.S.A. as Represented by the Secretary, Department Of Health and Human Services
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705
CPC分类号： C07K16/28 , A61K35/00 , A61K38/00 , A61K2039/505 , C07K14/4748 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K16/30 , C07K2317/21 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03
摘要： The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.055 秒)
